Companies / China
Taro Rejects Sun Merger
May 2008 | Company Finance AlertSurprising many industry observers, BMI included, on May 28 Israel's Taro Pharmaceutical Industries terminated its proposed merger with India's Sun Pharmaceutical Industries, bringing to an end a year-long saga. Taro deemed Sun's offer to raise the merger price to US$10.25 per share (up from an original offer of US$7.75 per share) still inadequate.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
